The stock price of Verona Pharma Plc ADR (NASDAQ: VRNA) has dropped by -4.22 compared to previous close of 36.93. Despite this, the company has seen a fall of -7.36% in its stock price over the last five trading days. cnbc.com reported 2024-11-09 that Verona Pharma has seen its share price skyrocket in anticipation of the commercial launch of its COPD treatment.
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
Company’s 36-month beta value is 0.44.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRNA is 65.84M, and currently, short sellers hold a 11.43% ratio of that floaft. The average trading volume of VRNA on November 15, 2024 was 1.04M shares.
VRNA’s Market Performance
VRNA’s stock has seen a -7.36% decrease for the week, with a 3.94% rise in the past month and a 28.66% gain in the past quarter. The volatility ratio for the week is 4.98%, and the volatility levels for the past 30 days are at 4.93% for Verona Pharma Plc ADR The simple moving average for the last 20 days is -1.70% for VRNA’s stock, with a simple moving average of 64.48% for the last 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Wells Fargo repeating the rating for VRNA by listing it as a “Overweight.” The predicted price for VRNA in the upcoming period, according to Wells Fargo is $50 based on the research report published on October 03, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $38, previously predicting the price at $35. The rating they have provided for VRNA stocks is “Buy” according to the report published on May 22nd, 2023.
Wedbush gave a rating of “Outperform” to VRNA, setting the target price at $27 in the report published on September 19th of the previous year.
VRNA Trading at 8.54% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.86% of loss for the given period.
Volatility was left at 4.93%, however, over the last 30 days, the volatility rate increased by 4.98%, as shares surge +2.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.85% upper at present.
During the last 5 trading sessions, VRNA fell by -7.36%, which changed the moving average for the period of 200-days by +92.75% in comparison to the 20-day moving average, which settled at $35.98. In addition, Verona Pharma Plc ADR saw 77.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from ZACCARDELLI DAVID, who sale 2,400 shares at the price of $5.00 back on Nov 11 ’24. After this action, ZACCARDELLI DAVID now owns 15,202,352 shares of Verona Pharma Plc ADR, valued at $12,000 using the latest closing price.
Hahn Mark W, the Chief Financial Officer of Verona Pharma Plc ADR, sale 2,400 shares at $5.00 during a trade that took place back on Nov 11 ’24, which means that Hahn Mark W is holding 14,291,336 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -23.71 for the present operating margin
- 0.8 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -23.45. The total capital return value is set at -0.44. Equity return is now at value -78.35, with -45.78 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -45.11. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -11.15.
Currently, EBITDA for the company is -52.47 million with net debt to EBITDA at 2.55. When we switch over and look at the enterprise to sales, we see a ratio of 390.1. The receivables turnover for the company is 0.95for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.03.
Conclusion
In a nutshell, Verona Pharma Plc ADR (VRNA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
